Treeline Announces $200M Funding Boost, Moves Three Cancer Drugs into Clinic

Treeline Biosciences closed a $200 million Series A extension, bringing total funding to $1.1 billion.13

The company initiated Phase 1 clinical trials for three programs:
TLN-121 (a BCL6 degrader for lymphoma), TLN-372 (a pan-KRAS inhibitor for solid tumors with KRAS mutations), and TLN-254 (an EZH2 inhibitor for lymphoma, licensed from Jiangsu Hengrui Pharmaceuticals).12345

The BCL6 degrader and KRAS inhibitor programs were internally discovered, while the EZH2 inhibitor was in-licensed.134

TLN-372 targets a major therapeutic gap, as about one in four adult cancers have KRAS gene mutations, but most variants currently lack effective targeted treatments.25

Treeline expects Phase 1 trial data in 2026 and plans to submit an IND for a fourth program in early 2026.3

The trials are enrolling patients with a range of lymphomas and solid tumors carrying relevant mutations.25

Sources:

1. https://treeline.bio/press/treeline-announces-first-clinical-trials-and-secures-usd200m-in-additional-funding

2. https://pulse2.com/treeline-biosciences-200-million-additional-funding-raised-and-first-clinical-trials-announced/

3. https://www.fiercebiotech.com/biotech/treeline-biosciences-reaps-200m-series-extension-picks-first-three-clinical-fruit

4. https://www.biopharmadive.com/news/secretive-startup-treeline-unveils-first-clinical-candidates-200m-in-new/759103/

5. https://trial.medpath.com/news/6cdf0ee693356f7c/treeline-biosciences-initiates-three-phase-1-trials-targeting-bcl6-kras-and-ezh2-with-1-1b-in-total-funding